NEW YORK, 25 November 2021 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (“Kura” or the “Company”) (NASDAQ: KURA). These investors are advised to contact Robert S. Willoughby To [email protected] or 888-476-6529, ext. 7980.
The investigation examines whether Kura and any of its officers and / or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
At November 24, 2021, Kura “announced that the United States Food and Drug Administration (FDA) has placed phase KOMET-001 1b Study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on partial clinical hold.[t]The partial clinical suspension was initiated following the Company’s recent report to the FDA of a serious grade 5 adverse event (patient death) potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of the AML[,]” and that “[u]Until the partial clinical suspension is resolved and the company has more clarity regarding the impact on the schedule, Kura suspends guidance on completing recruitment in the KOMET-001 phase 1b Study and Determination of the Recommended Phase 2 Dose of KO-539. ”
On this news, Kura’s stock price fell $ 2.58 per share, or 15.54%, to close at $ 14.02 to November 24, 2021.
Pomerantz LLP, with offices in new York, Chicago, Los Angeles, Paris, and Tel Aviv, is recognized as one of the leading firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class actions bar, Pomerantz was a pioneer in the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breach of fiduciary duty and professional misconduct. The firm has recovered numerous multi-million dollar damages on behalf of the members of the group. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext 7980
SOURCE Pomerantz LLP